Skip to main content
Galapagos NV logo

Galapagos NV — Investor Relations & Filings

Ticker · GLPG ISIN · BE0003818359 LEI · 549300QKJ78IY0IOV655 BR Manufacturing
Open in API
Filings indexed 2,867 across all filing types
Latest filing 2015-06-19 Share Issue/Capital Cha…
Country BE Belgium
Listing BR GLPG

About Galapagos NV

https://www.glpg.com/

Galapagos NV is a biotechnology company focused on transforming patient outcomes through scientific innovation. The company is strategically concentrating its efforts on its cell therapy platform, which is engineered for the scalable, decentralized, and rapid production of next-generation treatments. A key feature of this platform is a median 7-day vein-to-vein delivery time. In parallel with this focus, Galapagos is actively seeking partners to take over its portfolio of small molecule assets, including its TYK2 inhibitor program for autoimmune indications. This strategic shift allows the company to prioritize the growth and development of its cell therapy pipeline through internal discovery, partnerships, and acquisitions.

Recent filings

Filing Released Lang Actions
Share capital increase 19 June 2015_NL_FINAL.pdf
Share Issue/Capital Change Classification · 99% confidence The document announces a capital increase resulting from the exercise of warrants, leading to the issuance of new shares and an increase in the company's share capital. It explicitly mentions the total number of voting rights and outstanding securities, which relates to changes in the capital structure. This aligns directly with the definition of 'Capital/Financing Update' (CAP). Although it mentions transparency laws regarding shareholding changes, the primary focus is the capital raise via warrant exercise, making CAP the most specific fit over MRQ or SHA, as it details the financing mechanism used.
2015-06-19 Dutch
Galapagos completes recruitment for ORIGIN Phase 2 trial with GLPG1205 in ulcerative colitis patients
Regulatory Filings Classification · 92% confidence The document is a press release dated June 18, 2015, announcing that Galapagos has completed recruitment for its Phase 2 clinical trial (ORIGIN) for GLPG1205 in ulcerative colitis patients and expects topline results in Q1 2016. It details the trial design, the mechanism of action of the drug, and provides general company information. This type of announcement, focusing on clinical trial milestones and providing key updates without being a full financial report (like 10-K or IR) or a transcript, most closely aligns with an Earnings Release (ER) or a general announcement. Since it is a specific operational/clinical update rather than a formal financial results announcement, and it is not a presentation (IP) or a formal regulatory filing notice (RPA/RNS), it fits best under the 'Earnings Release' category as it signals upcoming data which is often tied to investor reporting cycles, or potentially 'Regulatory Filings' (RNS) if it were a mandatory disclosure. Given the content is a major operational update with forward-looking statements about future results, 'ER' (Earnings Release) is the closest fit among the provided options for a significant, non-financial-statement-based operational update that drives investor interest, although 'RNS' is a strong secondary candidate if this were purely a mandatory disclosure outside of scheduled earnings. However, based on the structure and content (clinical progress update), 'ER' is often used broadly for such announcements in some databases, but since it is not explicitly reporting *financial* results, 'RNS' (Regulatory Filings/General Announcement) is the safest classification for a non-standard report announcement. Given the options, and recognizing this is a major operational milestone announcement, I will classify it as a general Regulatory Filing/Announcement (RNS) as it is a specific, time-sensitive corporate update that doesn't fit the other specific categories like DIV, CAP, or CT.
2015-06-18 English
Galapagos completes recruitment for ORIGIN Phase 2 trial with GLPG1205 in ulcerative colitis patients
Regulatory Filings Classification · 95% confidence The document is a press release dated June 18, 2015, from Galapagos NV. It announces that patient recruitment for a Phase 2 clinical study (ORIGIN) involving drug candidate GLPG1205 for ulcerative colitis has been completed. It details the study design, mechanism of action, and expected timeline for results (Q1 2016). This type of announcement, focusing on clinical trial progress and key operational milestones rather than comprehensive financial results (like a 10-K or IR) or a formal earnings summary (ER), is best classified as a general corporate or regulatory announcement. Since it is a specific update on R&D progress and not a standard financial report, it fits best under the general 'Regulatory Filings' (RNS) category, as it is a material update released to the public/regulators, or potentially an Investor Presentation (IP) if it were a slide deck, but as a text release, RNS is the most appropriate fallback for non-standard, material corporate news not covered by other specific codes (like DIV, CAP, or ER). Given the context of a clinical trial update, it is a material event disclosure.
2015-06-18 English
SC 13G Filing
Major Shareholding Notification
2015-06-18 English
Galapagos rondt werving van patiënten af voor ORIGIN Fase 2 klinische studie met GLPG1205 bij colitis ulcerosa patiënten
Regulatory Filings Classification · 95% confidence The document is dated June 18, 2015, and is titled with a regulatory announcement header ("Gereglementeerde informatie"). The content announces the completion of patient recruitment for a Phase 2 clinical study (ORIGIN) involving drug candidate GLPG1205 for ulcerative colitis. This type of announcement, detailing progress in clinical trials and pipeline updates, is characteristic of general investor or regulatory news releases from a biotech company. It is not a full Annual Report (10-K), a formal Audit Report (AR), a Dividend Notice (DIV), or a specific management remuneration report (DEF 14A). Since it is a specific announcement about clinical trial progress and pipeline status, it fits best under the general category for corporate news that isn't a specific financial release like ER or IR. Given the options, this is a specific corporate update that doesn't fit the highly specific financial/governance codes. It is most closely related to general investor relations updates. While it contains clinical trial details, it is an announcement of a milestone, not a comprehensive Interim Report (IR) or Earnings Release (ER). It is best classified as a general Regulatory Filing (RNS) as it is a formal announcement of a material event, or potentially Investor Presentation (IP) if it were a slide deck, but it reads like a press release. Given the nature of reporting clinical milestones, RNS serves as the most appropriate general regulatory announcement category when a more specific clinical trial update code is unavailable.
2015-06-18 Dutch
6-K Filing
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed with the SEC by a foreign private issuer, Galapagos NV, for the month of June 2015. Form 6-K is a report of foreign private issuers to provide information that is made public in their home country or filed with a foreign stock exchange. The document is short (1248 characters) and includes a press release as an exhibit. There is no substantive financial data or detailed report content within the text itself, only a reference to an exhibit. According to the rules, such filings that are regulatory announcements or miscellaneous filings that do not fit other categories are classified as Regulatory Filings (RNS).
2015-06-16 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.